Merck’s first quarter results drew a positive market reaction, reflecting operational resilience despite a 1.6% ...

A draft agenda for an upcoming meeting of CDC vaccine experts indicated on Wednesday that there would be no discussion about ...

There’s reason to remain bullish about Merck’s growth prospects in the long run. And at a discounted price, the stock could ...

Enlicitide, which could be the first oral medication that blocks the protein PCSK9, helped cut cholesterol levels in a pair ...

Merck launches AI-powered search, offering patients fast, trusted answers from its widely used medical manuals and resources.

Gen Z grads are slamming degrees as worthless—but Fortune 500 boss, Doina Ionescu, says her MBA was the best investment ...

CareTrust, Merck, and Allete have rewarded shareholders for years and recently announced dividend increases. These companies ... Shareholders of Merck would probably like to forget the past six ...

Merck's oral cholesterol pill succeeded in two late-stage studies, marking a win for the drugmaker as it focuses on the ...

Merck has received approval from the Food and Drug Administration to expand use of its blockbuster drug, Keytruda, to treat ...

Merck & Co.’s Keytruda has become the first immunotherapy approved by the FDA to be used around surgery to treat resectable ...

The simplicity of Merck's monoclonal antibody for RSV in infants could be a plus in its competition with AstraZeneca's existing treatment.

South Korea's Dongjin Semichem has licensed its OLED material patents to major companies, including Germany's Merck and Japan ...